Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T
' In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy]. 'MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
More News: Cancer & Oncology | Hematology